In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's Innovation Bar and the Need for Less Impersonal Medicine

Executive Summary

Key to Pharma's future success will be the ability to identify subpopulations and develop drugs for them. This is not quite the one-drug-for-one-patient fantasy of "personalized medicine," but a significant departure from the one-size-fits-all therapy represented by blockbuster drugs like Lipitor is necessary. This change is driven by increasing costs of large studies, growing demand for more than drug-versus-placebo evidence when a new product wants to take on the standard of care, and more intense attention to safety.
Advertisement

Related Content

Shadow FDA? Researchers Are Taking Approval Matters into their Own Hands
Positioning Acomplia: Has the Drug Arrived Before the Disease?
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel